Cost-effectiveness analysis of pembrolizumab plus standard chemotherapy versus chemotherapy alone for first-line treatment of metastatic non-squamous non–small-cell lung cancer in China-Reference-Cited by-同舟云学术

Cost-effectiveness analysis of pembrolizumab plus standard chemotherapy versus chemotherapy alone for first-line treatment of metastatic non-squamous non–small-cell lung cancer in China

Published:2020-07-31 Issue: Volume: Page:ejhpharm-2020-002208
ISSN:2047-9956
Container-title:European Journal of Hospital Pharmacy
language:en
Short-container-title:Eur J Hosp Pharm

Author:

Jiang Yuan,Wang Xingwei^ORCID

Publisher

BMJ

Subject

General Pharmacology, Toxicology and Pharmaceutics

Reference21 articles.

1. Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

2. Global cancer statistics

3. Epidemiology of Lung Cancer Prognosis: Quantity and Quality of Life

4. Analysis of stage and clinical/prognostic factors for lung cancer from SEER registries: AJCC staging and collaborative stage data collection system;Chen;Cancer,2014

5. Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting;Abernethy;PLoS One,2017

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness of first-line immunotherapy combinations with or without chemotherapy for advanced non-small cell lung cancer: a modelling approach;BMC Cancer;2024-07-22

2. Cost-effectiveness analysis of the tislelizumab versus docetaxel for advanced or metastatic non-small-cell lung cancer in China;Frontiers in Public Health;2024-07-18

3. Comparison of Efficacy, safety, and cost-effectiveness of pembrolizumab versus chemotherapy for patients with advanced non-small cell lung cancer: a real-world study;2024-04-25

4. Real-world cost- effectiveness analysis: Tumor Treating Fields for newly diagnosed glioblastoma in China;Journal of Neuro-Oncology;2024-04-02

5. Clinical outcomes and medical resource utilization of toripalimab combination therapy versus bevacizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer;Current Medical Research and Opinion;2024-01-22